Sagal Pannu, Associate Research Scholar at OU Health Stephenson Cancer Center, posted on X:
“Stellar talk by Rafeh Naqash on tarlatamab and emerging bispecific T-cell engagers changing the treatment landscape of SCLC, understanding the mechanism of action and toxicities as well as management strategies to optimise use!”
Read Further: 15 Posts Not to Miss from the 3rd Day of ASCO 2025.